US5468753A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
Assignee: Sanofi Aventis France
•
Filing: 1993-10-20
•
Granted: 1995-11-21
•
Expires: 2013-10-20
Abstract
Abstract The invention concerns the use of i.a. 1-[2-(2-naphthyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and its pharmaceutically acceptable addition salts for the preparation of medicaments suitable for the treatment and/or prophylaxis of neuronal degenerative processes including senile dementia, vascular dementia, and Alzheimer's disease.
Inventors
- 👤 Francois X. Coude
- 👤 Jacqueline Fournier
- 👤 Umberto Guzzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 17:11
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/475; A61K31/44; A61P; A61P25/00; A61P25/28; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5082; G01N33/5088
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
64 words
A method for treating a mammal having a disorder which raises said mammal's susceptibility to neuronal degenerative processes which comprises administering a compound or a pharmaceutically acceptable salt thereof to said mammal having said disorder; said compound having the formula: ##STR2## wherein said compound is chronically administered in a pharmaceutically effective amount to reduce said susceptibility to neuronal degenerative processes associated with said disorder.
Claim 2
Independent Claim
64 words
A method for treating a mammal having a disorder which raises said mammal's susceptibility to neuronal degenerative processes which comprises administering a compound or a pharmaceutically acceptable salt thereof to said mammal having said disorder; said compound having the formula: ##STR2## wherein said compound is chronically administered in a pharmaceutically effective amount to reduce said susceptibility to neuronal degenerative processes associated with said disorder.
Claim 3
Dependent Claim
61 words
The method of claim 1 wherein said disorder is selected from the group consisting of memory impairments, vascular dementia, post-encephalitic disorders, post-apoplectic disorders, post-traumatic syndrome caused by brain injury, cerebral anoxic diseases, Alzheimer's disease, senile dementia, subcortical dementia including Huntington's chorea and Parkinson's disease, AIDS dementia, neuropathies provoked by sympathetic or sensory nerve necrosis or lesions, cerebral oedema and spinocerebellar degenerations.
Claim 4
Dependent Claim
22 words
The method of claim 2 wherein said disorder is selected from the group consisting of vascular dementia, senile dementia and Alzheimer's disease.
Claim 5
Dependent Claim
22 words
The method of claim 1 wherein the compound of formula (I) is 1-2 [2-(2-naphthyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or a pharmaceutically acceptable acid addition salt thereof.
References Cited (Backward Citations)
US5026716A
Cited
FR2662355A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-11-20 | 1999-05-22 | 1999-11-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-11-20 | 2003-05-22 | 2003-11-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-11-20 | 2007-05-22 | 2007-11-21 | $7700.00 | Window Closed / Lapsed |